September 13, 2017
1 min read

Research supports further refinement of PIXL for low myopia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Significant improvements were found in uncorrected distance visual acuity, manifest sphere and manifest refraction spherical equivalent at all visits after photorefractive intrastromal corneal crosslinking for the treatment of myopic refractive errors.

“Photorefractive intrastromal CXL is a minimally invasive procedure that does not require stromal tissue removal; rather, it aims to cause a biomechanical shift that leads to central flattening without compromising the structural integrity of the cornea,” according to the study authors.

Twenty-six eyes from 14 healthy patients with myopia or myopic astigmatism underwent photorefractive intrastromal CXL, or PIXL, using the Mosaic system to apply ultraviolet-A (UVA) 365 nm (30 mW/cm2) irradiance with riboflavin 0.1% solution.

Mean patient age was 30.8 years.

At 1, 3 and 6 months postoperatively, there were statistically significant improvements in uncorrected distance visual acuity.

Researchers also observed a significant improvement in corrected distance visual acuity.

Corneal curvature was significantly reduced versus baseline at all follow-up visits.

Photorefractive intrastromal CXL is not intended as a substitute for these treatments, and researchers suggest that a CXL procedure can be used to reduce the refractive errors in normal healthy eyes and provide an option for patients with low myopia who want refractive improvement without traditional surgery.

The researchers concluded that this study provides support for further development of a refined treatment approach for this new minimally invasive treatment. – by Abigail Sutton

Disclosure: The researchers report no relevant financial disclosures.